Skip to content
Review Open access

Comparative Efficacy of Aldosterone‐Related Sodium‐Retention Pathway Therapies for Resistant Hypertension: A Drug‐Level Network Meta‐Analysis of Randomized Controlled Trials

Sep 2026 · The Journal of Clinical Hypertension · Vol 28 · 0 citations · 58 references
Medicine

TL;DR

The aldosterone‐related sodium‐retention pathway as an important therapeutic target in RH is supported, and newer ASIs and amiloride may represent pathway‐based alternatives for selected patients.

Abstract

Mineralocorticoid receptor antagonists (MRAs), aldosterone synthase inhibitors (ASIs), and epithelial sodium channel (ENaC) blockade target different levels of the aldosterone‐related sodium‐retention pathway in resistant hypertension (RH), but the comparative efficacy of individual agents remains uncertain. We conducted a focused drug‐level network meta‐analysis of randomized controlled trials (RCTs) comparing pathway‐directed therapies in adults with RH. PubMed, Scopus, Embase, Cochrane CENTRAL, Cochrane Reviews, and ClinicalTrials.gov were searched from inception to July 20, 2026. The primary outcome was change in office systolic blood pressure (BP). Secondary outcomes included office diastolic BP and 24‐hour ambulatory systolic and diastolic BP. Ten RCTs including 2865 participants were analyzed. In the primary drug‐level analysis, amiloride, spironolactone, baxdrostat, eplerenone, and lorundrostat significantly reduced office systolic BP compared with placebo, with mean differences (MDs) of −14.08, −10.78, −9.09, −8.14, and −6.80 mmHg, respectively. Osilodrostat showed a statistically uncertain effect, with an MD of −2.61 mmHg. At the class level, both MRAs and ASIs showed clinically meaningful reductions in office systolic BP. Secondary outcomes were generally consistent with the primary analysis, although fewer trials contributed to these networks. Sensitivity analyses did not materially change the primary findings. These results support the aldosterone‐related sodium‐retention pathway as an important therapeutic target in RH. MRAs remain the established reference add‐on therapy, whereas newer ASIs and amiloride may represent pathway‐based alternatives for selected patients.

Read PDF

Similar papers

Review Open access Oct 2026

Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials

Overall, ASIs have strong short-term placebo-adjusted effects on BP, but direct RCT comparisons between ASIs and MRAs are required; therefore, class comparison is indirect and must be interpreted cautiously.

Girin Ray, D. Sanyal · 0 citations
Review Open access Oct 2026

Blood Pressure-Lowering Effects of Finerenone: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...

G. Marino, S. D. Di Fusco, E. Graziano et al. · 0 citations
Open access Sep 2026

Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.

INTRODUCTION Dysregulated aldosterone plays an important role in the pathogenesis of hypertension (HTN) and chronic kidney disease (CKD). Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated efficacy and safety for uncontrolled HTN (uHTN) and treatment-resistant HTN in multiple well-control...

M. Weir, S. Bhaduri, Keung Lee et al. · 1 citation
Review Open access Sep 2026

Efficacy and Safety of Oral Non‐Statin Lipid‐Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta‐Analysis

ABSTRACT Introduction Dyslipidaemia remains a major contributor to atherosclerotic cardiovascular disease (ASCVD), and many patients fail to achieve recommended low‐density lipoprotein cholesterol (LDL‐C) targets despite statin therapy or are unable to tolerate statins. Oral non‐statin therapies have emerged as importa...

Tamer Hodrob, Reem J. Saad, Aya Hamdy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.